Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASGR1 | P07306 | 9/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16008570 | 1.00 | ASGR1 (0.38) | ASGR1 | |
| SCHEMBL16691272 | 1.00 | ASGR1 (0.38) | ASGR1 | |
| SCHEMBL7109122 | 1.00 | ASGR1 (0.38) | ASGR1 | |
| Guanidine SCHEMBL19475676 | 0.91 | ASGR1 (0.34) | ASGR1 | |
| SCHEMBL24256008 | 0.88 | ASGR1 (0.45) | ASGR1 | |
| Uracil SCHEMBL7108401 | 0.78 | CRBN (0.44) | — | |
| Thymine SCHEMBL19474978 | 0.77 | ATAD2 (0.46) | ASGR1 | |
| Thymine SCHEMBL7107663 | 0.77 | ATAD2 (0.46) | ASGR1 | |
| Adenine SCHEMBL19474976 | 0.75 | HSP90B1 (0.33) | — | |
| SCHEMBL24268197 | 0.73 | ASGR1 (0.37) | ASGR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002716-A1 | TRINUCLEOTIDE CAP ANALOGS, PREPARATION AND USES THEREOF | Life Technologies Corporation | 2022-01-06 | — | — | US | disclosed |
| WO-2022006368-A2 | TRINUCLEOTIDE CAP ANALOGS, PREPARATION AND USES THEREOF | Life Technologies Corporation (US) | 2022-01-06 | — | — | WO | disclosed |
| US-10968248-B2 | Trinucleotide mRNA cap analogs | Arcturus, Inc. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10570388-B2 | Phosphate replacement MRNA cap analogs | MODERNATX, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10563195-B2 | Phosphate replacement mRNA cap analogs | MODERNATX, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20200040026-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | ARCTURUS THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-20190225644-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | MODERNATX, INC. | 2019-07-25 | — | — | US | disclosed |
| US-20190218546-A1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | MODERNATX, INC. | 2019-07-18 | — | — | US | disclosed |
| US-20190211368-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | MODERNATX, INC. | 2019-07-11 | — | — | US | disclosed |
| WO-2018075827-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | ARCTURUS THERAPEUTICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| US-20180105551-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | ARCTURUS THERAPEUTICS, INC. | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105551-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | RNGTT, RNMT, NSUN2 | ASGR1 3471/4885 |
| US-20190211368-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | RNGTT, RNMT, CPSF7 | ASGR1 3744/4885 |
| US-20220002716-A1 | TRINUCLEOTIDE CAP ANALOGS, PREPARATION AND USES THEREOF | RNGTT, RNMT, CPSF7 | ASGR1 3548/4885 |
| US-20200040026-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | RNGTT, RNMT, NSUN2 | ASGR1 3471/4885 |
| US-10570388-B2 | Phosphate replacement MRNA cap analogs | RNGTT, RNMT, CPSF6 | ASGR1 1908/4885 |
| US-10968248-B2 | Trinucleotide mRNA cap analogs | RNGTT, RNMT, NSUN2 | ASGR1 3471/4885 |
| US-20190218546-A1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | RNGTT, RNMT, CPSF7 | ASGR1 3453/4885 |
| US-10563195-B2 | Phosphate replacement mRNA cap analogs | RNGTT, RNMT, CPSF6 | ASGR1 1908/4885 |
| US-20190225644-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | RNGTT, RNMT, NSUN2 | ASGR1 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.